Myopericarditis in a previously healthy adolescent male following COVID-19 vaccination: A case report
- PMID: 34133825
- PMCID: PMC8441784
- DOI: 10.1111/acem.14322
Myopericarditis in a previously healthy adolescent male following COVID-19 vaccination: A case report
Abstract
We report the case of a previously healthy 16-year-old male who developed myopericarditis following the second dose of his Pfizer-BioNTech COVID-19 vaccine, with no other identified triggers. Adolescents and young adults experiencing chest pain after COVD-19 vaccination should seek emergent medical care, and emergency providers should have a low threshold to consider and evaluate for myopericarditis. More data are needed to better understand the potential association between COVID-19 vaccines and myopericarditis. If a true causal link is identified, the risk must also be viewed in context with the millions of patients who have been safely vaccinated and the known morbidity and mortality from COVID-19 infection. As we see widespread vaccine rollout, it is important that all potential adverse reactions are reported as we continue to monitor for more rare but potentially serious side effects not identified in vaccination trials.
Keywords: COVID-19; myocarditis.
© 2021 by the Society for Academic Emergency Medicine.
Comment in
-
Akute Myokarditis nach mRNA-Impfung gegen COVID-19.Rofo. 2022 Apr;194(4):422-424. doi: 10.1055/a-1676-4773. Epub 2021 Nov 18. Rofo. 2022. PMID: 34794189 German. No abstract available.
References
-
- Health Department‐Reported Cases of Multisystem Inflammatory Syndrome in Children (MIS‐C) in the United States . Centers for Disease Control and Prevention website. 2021. Accessed May 25, 2021. https://www.cdc.gov/mis‐c/cases/index.html
-
- Patrick SW, Henkhaus LE, Zickafoose JS, et al. Well‐being of parents and children during the COVID‐19 pandemic: a national survey. Pediatrics. 2020;146(4):e2020016824. - PubMed
-
- Commissioner of the Coronavirus (COVID‐19) Update: FDA Authorizes Pfizer‐BioNTech COVID‐19 Vaccine for Emergency Use in Adolescents in Another Important Action in Fight Against Pandemic . U.S. Food and Drug Administration website. 2021. Accessed May 26, 2021. https://www.fda.gov/news‐events/press‐announcements/coronavirus‐covid‐19...
-
- A PHASE 1/2/3, PLACEBO‐CONTROLLED, RANDOMIZED, OBSERVER‐BLIND, DOSE‐FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS‐COV‐2 RNA VACCINE CANDIDATES AGAINST COVID‐19 IN HEALTHY INDIVIDUALS . 2020. Accessed May 26, 2021. https://cdn.pfizer.com/pfizercom/2020‐11/C4591001_Clinical_Protocol_Nov2...
-
- COVID‐19 VaST Technical Report May 17, 2021 . Centers for Disease Control and Prevention website. 2021. Accessed May 25, 2021. https://www.cdc.gov/vaccines/acip/work‐groups‐vast/technical‐report‐2021...
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials